Clinical Research Directory
Browse clinical research sites, groups, and studies.
Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)
Sponsor: Epiliquid Holding, Inc
Summary
CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to assess the performance of Delta-HLD, Epiliquid's proprietary liquid biopsy technology, for colorectal cancer (CRC) detection. The study will evaluate the test performance in an average-risk population for CRC undergoing screening colonoscopy, which will serve as the gold standard reference.
Official title: Clinical Validation Cross-sectional Study for Colorectal Cancer Assessment Using Delta-HLD Technology (CLIMBED)
Key Details
Gender
All
Age Range
45 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
3200
Start Date
2024-04-04
Completion Date
2028-12
Last Updated
2025-09-11
Healthy Volunteers
Yes
Conditions
Locations (1)
Epiliquid
Mendoza, Mendoza Province, Argentina